Moderator: SABCS Co-director Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine T-DM1 Improved Overall Survival for Heavily Pretreated Patients With HER2-positive Breast Cancer; Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-free Survival; No Significant Difference in Recurrence Rates Among Women With DCIS Taking Anastrozole or Tamoxifen; and DCIS Patients Receiving Anastrozole Reported Symptoms Different From Those Receiving Tamoxifen.

Moderator: SABCS Co-director and AACR Past-president Carlos L. Arteaga, MD, director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center Analysis of Blood Samples Finds ESR1 Gene Mutations Are Prevalent and Associated With Worse Overall Survival; Breast-conserving Therapy Yielded Better Outcomes Than Mastectomy For Early-stage Patients; Mastectomy Plus Reconstruction has Higher Complication Rates and Costs Than Lumpectomy Plus Radiation; and Resistance of ER-positive Breast Cancer to Tamoxifen Therapy May be Driven by APOBEC3B.

Moderator: SABCS Co-director Virginia Kaklamani, MD, leader of the Breast Cancer Program at the Cancer Therapy & Research Center and professor of medicine at the UT Health Science Center San Antonio Capecitabine Improved Outcomes for Breast Cancer Patients With Residual Disease After Presurgery Chemotherapy; Women With Luminal A Subtype of Breast Cancer Did Not Benefit From Adjuvant Chemotherapy; Denosumab Improves Disease-free Survival for Postmenopausal Patients With HR-positive Breast Cancer; and Pathologic Complete Response to Presurgery Chemotherapy Improves Survival For Patients With Triple-negative Breast Cancer.

The American Association for Cancer Research (AACR) announced the launch of an international initiative known as AACR Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE). The initial phase of the project, which is being conducted in partnership with seven global leaders in genomic sequencing for clinical utility, as well as two informatics partners, will aggregate project members’ clinical-grade sequencing data to improve patient treatment decisions and catalyze clinical and translational research. The seven founding members of the consortium and phase 1 participants are: The Center for Personalized Cancer Treatment, Utrecht, Netherlands; Dana-Farber Cancer Institute, Boston; Institut Gustave Roussy, Villejuif, France; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore; Memorial Sloan Kettering Cancer Center, New York; Princess Margaret Cancer Centre, Toronto; and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. The two informatics partners are: Sage Bionetworks, Seattle; and cBioPortal, New York.

On Friday, Nov. 6, a press conference was held featuring a preview of the meeting with the conference co-chairs: Levi A. Garraway, MD, PhD, Dana-Farber Cancer Institute, Boston (AACR); Lee J. Helman, MD, NCI, Bethesda, Maryland (NCI); and Jean-Charles Soria, MD, PhD, Institut Gustave Roussy, Villejuif, France (EORTC). The press conference also highlighted the following research: Loss of SMAD4 Gene in Certain Colorectal Cancers is Associated With Poor Prognosis; and Pediatric Low-grade Gliomas with CRAF Fusions May Require Differential and Combinatorial Targeted Therapies